



## **CYNTELLECT UK WORKSHOPS ATTRACT TOP STEM CELL RESEACHERS**

**WELWYN GARDEN CITY, ENG and EDINBURGH, SCT—December 1, 2010**—CynTellect, Inc., a privately-held life sciences company commercializing products to advance the study of cell biology, stem cell research, biopharmaceutical production, and drug discovery, has held three workshops across Europe to provide researchers with training on the LEAP™ Cell Processing Workstation. The LEAP workstation is an award-winning, microplate-based cytometry system used for *in situ* analysis, purification, and processing of virtually any cell type.

The Cell Purification Workshop was held on November 16 in the UK to demonstrate the use of LEAP technology to develop biopharmaceutical cell lines. Demonstrations included cell secretion cloning for the purpose of producing highly-secreting cell lines for bioproduction and purification of adherent cells which can be used to rapidly generate stable cell lines. Researchers from several prominent pharmaceutical companies, including GSK (GlaxoSmithKline), Novartis, and Servier took part in the training.

The Stem Cell Workshops were held on November 17 and 18 in the UK and SCT, respectively, to demonstrate the use of LEAP technology to automatically derive and propagate stem cell lines. Demonstrations included automated passaging, consistent embryoid body production, and isolation of specific stem cell colonies. Investigators from prestigious affiliations including Cancer Research-UK, Edinburgh University, Plasticell, Roslin Cells, and Servier took part in the training. "I was impressed by the technology, the quality of the segmentation, and the efficiency of the laser." said Christine OUVRY from the SERVIER Research Institute (Croissy sur Seine, France).

### **Media Contacts:**

info@cynTellect.com

### **About CynTellect**

CynTellect is dedicated to setting new standards in cell analysis, purification, and processing technology. CynTellect's products support key applications to advance life science research, biopharmaceutical production, and stem cell research and drug discovery. The Company's technology employs *in situ*, microplate-based cytometry to analyze cells with minimal sample manipulation, and process cells with great precision and efficiency. CynTellect's expanding cellular analysis and processing portfolio is expected to play an enabling role in the coming age of advanced cell-based diagnostics and therapeutics.